

**ADDITIONAL FILE 4. Characteristics of studies testing if My5-FU is clinically equivalent to LC-MS/MS**

Study <i>Sample N</i> <i>Source</i>	Range of plasma concentrations * (ng/mL)	Correlation	Automation of My5-FU assay	Bland-Altman Plot		
				Bias (95%CI)	Lower & upper limits of agreement	Largest outliers
Buchel, 2013[38] 247 <i>GI cancers</i>	93 to 17881	R <sup>2</sup> =0.99** Slope 1.08 (95% CI 1.06 to 1.09)	Roche Cobas Integra 800 analyser	7.0% (5.5 to 8.5)	-18% 30% §§	-50% +95% §§
Beumer, 2009[15] 156 <i>Head and Neck and colorectal cancer</i>	93-1774	R <sup>2</sup> =0.97 Slope 1.035 Intercept 10.9ng/mL	Olympus AU400 analyser	+ 23ng/mL (NR)	NR	-35% +52% §§
Makihara 2012[39] 50 <i>colorectal cancer</i> §	41-457	R <sup>2</sup> =0.8471	None or NR	NR	NR	NR

*\*as measured by the index test; \*\*Passing-Bablok regression[52] ; § patients received prodrug; §§ read from plot ,capecitabine; NR = not reported;*